Other assets impairments, restructuring and other items

12 Months Ended

Dec. 31, 2023

Other assets impairments, restructuring and other items

NOTE 15—Other asset impairments, restructuring and other items:


	Year ended December 31,
	2023		2022		2021
	(U.S. $ in millions)
Impairment of long-lived tangible assets (1)	$	28	$	47	$	160
Contingent consideration (see note 20) (2)		548		261		7
Restructuring		111		146		133
Other		30		57		41

Total	$	718	$	512	$	341

(1)	Including impairments related to exit and disposal activities.

(2)	The contingent consideration presented in the tables above for the year ended December 31, 2022 have been revised as discussed in note 1b.

Impairments

Impairments of tangible assets for the years ended December 31, 2023, 2022 and 2021 were $28 million, $47 million and $160 million, respectively. Impairments for the year ended December 31, 2023 were mainly related to certain assets in Europe and North America. Impairments for the year ended December 31, 2022 were mainly related to certain assets North America. Impairments for the year ended December 31, 2021 were mainly related to certain assets in Europe and North America.

Teva may record additional impairments in the future, to the extent it changes its plans on any given asset and/or the assumptions underlying such plans, as a result of its network consolidation activities and its “Pivot to Growth Strategy”.

Contingent consideration

In 2023, Teva recorded expenses of $548 million for contingent consideration, compared to expenses of $261 million in 2022 and $7 million in 2021. Expenses in 2023 were mainly related to a change in the estimated future royalty payments to Allergan in connection with lenalidomide (generic equivalent of Revlimid

) and a change in the estimated future royalty payments to Eagle in connection with expected future bendamustine sales. Expenses in 2022, which were revised as discussed in note 1b, were mainly related to changes in the estimated future royalty payments to Allergan in connection with lenalidomide (generic equivalent of Revlimid

Restructuring

In 2023, Teva recorded $111 million of restructuring expenses, compared to $146 million in 2022 and $133 million in 2021. Expenses in 2023 and 2022 were primarily related to network consolidation activities. Expenses in 2021 were primarily related to network consolidation activities and residual expenses of the restructuring plan announced in 2017.

The following table provides the components of restructuring costs:


	Year ended December 31,
	2023		2022		2021
	(U.S. $ in millions)
Restructuring
Employee termination	$	52	$	117	$	117
Other		59		29		16

Total	$	111	$	146	$	133

The following table provides the components of and changes in the Company’s restructuring accruals:


	Employee termination costs			Other			Total
	(U.S. $ in millions )
Balance as of January 1, 2021	$	(115	)	$	(7	)	$	(122	)

Provision		(117	)		(16	)		(133	)
Utilization and other*		101			16			117

Balance as of December 31, 2021	$	(131	)	$	(7	)	$	(138	)

Provision		(117	)		(29	)		(146	)
Utilization and other*		136			29			165

Balance as of December 31, 2022	$	(112	)	$	(7	)	$	(119	)

Provision		(52	)		(59	)		(111	)
Utilization and other*		90			59			149

Balance as of December 31, 2023	$	(75	)	$	(7	)	$	(82	)

*	Includes adjustments for foreign currency translation.